Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)

Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC). Fact Sheet Nr. 184.

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
251kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WV Otolaryngology > WV 300-358 Nose and paranasal sinuses WV Otolaryngology > WV 400-440 Pharyngeal region
Language:	English
Series Name:	Fact Sheet Nr. 184
Deposited on:	24 Sep 2024 10:25
Last Modified:	10 Jul 2025 11:38

Repository Staff Only: item control page